Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
40 hedge funds and large institutions have $2.73M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 7 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
9% less funds holding
Funds holding: 44 → 40 (-4)
17% less capital invested
Capital invested by funds: $3.3M → $2.73M (-$570K)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$56.4K |
| 2 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$36.5K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$10.3K |
| 4 |
VF
Virtu Financial
New York
|
+$2.48K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$1.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$53.5K |
| 2 |
JFGLC
Johnson Financial Group LLC (Colorado)
Denver,
Colorado
|
-$50K |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$34K |
| 4 |
CAC
Cowen and Company
New York
|
-$13.8K |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$11K |
DNA.WS Hedge Fund Activity: Q1 2023 in Review
40 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q1 2023, worth a combined $2.73M — down 17% from $3.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DNA.WS and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Walleye Capital, adding an estimated $56.4K. The largest seller was CVI Holdings, cutting an estimated $53.5K.
- 40 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q1 2023, down from 44 in Q4 2022.
- Funds reported $2.73M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q1 2023, down 17% quarter-over-quarter.
- 3 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q1 2023 and 7 closed out, a net change of -4 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q1 2023 was Walleye Capital, an estimated $56.4K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q1 2023 was CVI Holdings, an estimated $53.5K sold.
Based on aggregated 13F filings for Q1 2023.